Patents by Inventor Philip J. Provost

Philip J. Provost has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for preventing zoster or alleviating varicella related post-herpetic neuralgia
    Patent number: 6214354
    Abstract: Herpes Zoster, or varicella related post herpetic neuralgia is alleviated by immunizing people at risk of developing herpes zoster with varicella zoster virus (VZV) antigen.
    Type: Grant
    Filed: August 11, 1999
    Date of Patent: April 10, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Gary B. Calandra, Philip J. Provost, Myron J. Levin, C. Jo White
  • Method for alleviating varicella related post-herpetic neuralgia
    Patent number: 5997880
    Abstract: Herpes Zoster, or varicella related post herpetic neuralgia is alleviated by immunizing people at risk of developing herpes zoster with varicella zoster virus (VZV) antigen.
    Type: Grant
    Filed: March 18, 1994
    Date of Patent: December 7, 1999
    Assignees: Merck & Co., Inc., University of Colorado
    Inventors: Gary B. Calandra, Philip J. Provost, Myron J. Levin, C. Jo White
  • Cell culture of hepatitis A virus
    Patent number: 5766603
    Abstract: Hepatitis A virus is attenuated in virulence by in vitro passage in susceptible cell cultures, without prior passage in a subhuman primate. This process results in a live, attenuated hepatitis A virus vaccine suitable for human disease prevention.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: June 16, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Paula A. Giesa, Philip J. Provost, Maurice R. Hilleman
  • Thermostable varicella zoster virus
    Patent number: 5728386
    Abstract: A thermostable varicella zoster virus (tVZV) is useful for the preparation of a vaccine against chickenpox. The tVZV was selected from a population of virus which survived stringent heat inactivation conditions. The surviving virus is used to provide seed virus to produce a new vaccine with enhanced stability.
    Type: Grant
    Filed: May 22, 1996
    Date of Patent: March 17, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Philip J. Provost, Cathy Warren Wadsworth
  • Process for attenuated varicella zoster virus vaccine production
    Patent number: 5607852
    Abstract: A live, attenuated varicella zoster virus vaccine is produced with enhanced yield of VZV. The new process makes mass production of a live VZV vaccine more practical. In addition, optimized monoloyer cell culture conditions provide a process for maximizing monolayer cell density which is useful for enhancing viral vaccine production. According to this process, cell densities approaching 500,000 cells/cm.sup.2 are routinely achieved in conventional culture vessels.
    Type: Grant
    Filed: December 5, 1994
    Date of Patent: March 4, 1997
    Assignee: Merch & Co., Inc.
    Inventors: Philip J. Provost, David L. Krah, Paul A. Friedman
  • Cell culture of hepatitis A virus
    Patent number: 5514376
    Abstract: Hepatitis A virus is attenuated in virulence by in vitro passage in susceptible cell cultures, without prior passage in a subhuman primate. This process results in a live, attenuated hepatitis A virus vaccine suitable for human disease prevention.
    Type: Grant
    Filed: February 10, 1993
    Date of Patent: May 7, 1996
    Assignee: Merck & Co., Inc.
    Inventors: Paula A. Giesa, Philip J. Provost, Maurice R. Hilleman
  • Process for attenuated varicella zoster virus vaccine production
    Patent number: 5360736
    Abstract: A live, attenuated varicella zoster virus vaccine is produced with enhanced yield of VZV. The new process makes mass production of a live VZV vaccine more practical.
    Type: Grant
    Filed: June 4, 1992
    Date of Patent: November 1, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Philip J. Provost, David L. Krah, Paul A. Friedman
  • Attenuated hepatitis A virus
    Patent number: 5021348
    Abstract: Hepatitis A virus is attenuated by propagation in cell culture in vitro by direct inoculation of the cell cultures with a human clinical specimen containing the virus.
    Type: Grant
    Filed: May 14, 1984
    Date of Patent: June 4, 1991
    Assignee: Merck & Co., Inc.
    Inventors: Paula A. Giesa, Maurice R. Hilleman, Philip J. Provost
  • Growth of hepatitus A virus in vero cells
    Patent number: 4783407
    Abstract: Hepatitus A virus is grown in Vero cells after passage in in vitro cell culture. Virus replication and continued passage in Vero cells requires extended incubation times, up to about four weeks, for early passages and incubation temperatures no higher than about 32.degree. C. Continued passage results in a significant decrease in incubation time and an increase in virus yield. Cultivation of hepatitus A virus in Vero cells meets the development requirements for an inactivated human vaccine.
    Type: Grant
    Filed: September 30, 1985
    Date of Patent: November 8, 1988
    Assignee: Merck & Co., Inc.
    Inventors: Philip J. Provost, Paula A. Giesa, William J. McAleer
  • Hepatitis a virus cell culture in vitro
    Patent number: 4164566
    Abstract: Hepatitis A virus is passaged at least once in a susceptible sub-human primate; the infected liver from such passage is used to inoculate an in vitro cell culture, the inoculated cell culture is incubated until hepatitis A antigen is detected in the cell sheet or culture fluid, and at least two serial in vitro passages in cell culture are carried out. The hepatitis A virus so modified can be used to prepare live, attenuated hepatitis A vaccine or an inactivated hepatitis A vaccine.
    Type: Grant
    Filed: August 17, 1978
    Date of Patent: August 14, 1979
    Assignee: Merck & Co., Inc.
    Inventors: Philip J. Provost, Maurice R. Hilleman
  • Hepatitis A antigen
    Patent number: 4031203
    Abstract: Hepatitis A antigen obtained from the livers of non-human primates infected with hepatitis A (infectious hepatitis) virus has been found to be usable in fast, simple assays for hepatitis A antibody and thus usable in diagnosis of hepatitis A disease in humans, and for the preparation of hepatitis A vaccine.
    Type: Grant
    Filed: June 7, 1976
    Date of Patent: June 21, 1977
    Assignee: Merck & Co., Inc.
    Inventors: Philip J. Provost, Oswald L. Ittensohn, Maurice R. Hilleman
  • Hepatitis A antigen
    Patent number: 4029764
    Abstract: Hepatitis A antigen obtained from the livers of non-human primates infected with hepatitis A (infectious hepatitis) virus has been found to be usable in fast, simple assays for hepatitis A antibody and thus usable in diagnosis of hepatitis A disease in humans, and for the preparation of hepatitis A vaccine.
    Type: Grant
    Filed: December 9, 1974
    Date of Patent: June 14, 1977
    Assignee: Merck & Co., Inc.
    Inventors: Philip J. Provost, Oswald L. Ittensohn, Maurice R. Hilleman
  • Hepatitis A antigen
    Patent number: 4017601
    Abstract: Hepatitis A antigen obtained from the stools of patients infected with hepatitis A (infectious hepatitis) virus has been found to be usable in fast, simple assays for hepatitis A antibody and thus usable in diagnosis of hepatitis A disease, and for the preparation of hepatitis A vaccine.
    Type: Grant
    Filed: October 16, 1975
    Date of Patent: April 12, 1977
    Assignee: Merck & Co., Inc.
    Inventors: Maurice R. Hilleman, William J. Miller, Philip J. Provost